Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MLYS
MLYS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MLYS News
Mineralys Reports Positive Clinical Data for Lorundrostat in Heart Failure Risk
5d ago
NASDAQ.COM
Lorundrostat Significantly Reduces Heart Failure Risk Biomarkers
6d ago
Newsfilter
Mineralys Therapeutics Prices Stock Offering at $26.50
Jun 03 2026
seekingalpha
Mineralys Therapeutics Prices $150 Million Underwritten Offering
Jun 03 2026
Newsfilter
Velan Capital Reduces Stake in Mineralys Therapeutics
May 31 2026
NASDAQ.COM
Velan Capital Reduces Stake in Mineralys Therapeutics
May 31 2026
Fool
Lorundrostat Shows Significant Efficacy in Chronic Kidney Disease Patients
May 30 2026
Newsfilter
Mineralys Therapeutics Q1 2026 Earnings Call Highlights
May 07 2026
seekingalpha
Mineralys Grants Stock Options and RSUs to New Employees
May 05 2026
Newsfilter
Mineralys CEO Sells 75,000 Shares Amid Market Fluctuations
Apr 07 2026
Fool
Dell and Super Group See Surge in Options Trading Volume
Mar 31 2026
NASDAQ.COM
ETF Analysis: FTLS Implied Upside of 21.41%
Mar 20 2026
NASDAQ.COM
Mineralys Therapeutics Q4 2025 Earnings Call Highlights
Mar 13 2026
seekingalpha
Mineralys Therapeutics Q4 Earnings Beat Expectations
Mar 12 2026
seekingalpha
FDA Accepts Marketing Application for Mineralys' Lorundrostat
Mar 10 2026
seekingalpha
Mineralys Therapeutics' NDA for Lorundrostat Accepted by FDA
Mar 10 2026
NASDAQ.COM
Show More News
